A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran

Ximelagatran was developed for the prevention and treatment of thromboembolic conditions. However, in long-term clinical trials with ximelagatran, the liver injury marker, alanine aminotransferase (ALT) increased in some patients. Analysis of plasma samples from 134 patients was carried out using proteomic and metabolomic platforms, with the aim of finding predictive biomarkers to explain the ALT elevation. Analytes that were changed after ximelagatran treatment included 3-hydroxybutyrate, pyruvic acid, CSF1R, Gc-globulin, L-glutamine, protein S and alanine, etc. Two of these analytes (pyruvic acid and CSF1R) were studied further in human cell cultures in vitro with ximelagatran. A systems biology approach applied in this study proved to be successful in generating new hypotheses for an unknown mechanism of toxicity.

[1]  A Jawaid,et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.

[2]  P. Beaune,et al.  Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[3]  W. Kwon,et al.  Protective effects of ethyl pyruvate treatment on paraquat-intoxicated rats , 2008, Human & experimental toxicology.

[4]  J. van der Greef,et al.  The art and practice of systems biology in medicine: mapping patterns of relationships. , 2007, Journal of proteome research.

[5]  F. Guo,et al.  The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. , 2007, Cell metabolism.

[6]  D. Durden,et al.  Role of Glutamine Depletion in Directing Tissue-specific Nutrient Stress Responses to L-Asparaginase* , 2006, Journal of Biological Chemistry.

[7]  M. Speeckaert,et al.  Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[8]  E. Hinoi,et al.  A Molecular Mechanism of Pyruvate Protection against Cytotoxicity of Reactive Oxygen Species in Osteoblasts , 2006, Molecular Pharmacology.

[9]  E. Stanley,et al.  Colony-stimulating factor-1 in immunity and inflammation. , 2006, Current opinion in immunology.

[10]  T. Hankemeier,et al.  Microbial metabolomics with gas chromatography/mass spectrometry. , 2006, Analytical chemistry.

[11]  M. Holness,et al.  Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases , 2006, Archives of physiology and biochemistry.

[12]  P. Lenting,et al.  In Vivo Clearance of Human Protein S in a Mouse Model: Influence of C4b-Binding Protein and the Heerlen Polymorphism , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[13]  B. Bucher,et al.  Ethyl Pyruvate Ameliorates Liver Ischemia-Reperfusion Injury by Decreasing Hepatic Necrosis and Apoptosis , 2005, Transplantation.

[14]  William M. Lee,et al.  Hepatic Findings in Long-Term Clinical Trials of Ximelagatran , 2005, Drug safety.

[15]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[16]  A. Blom,et al.  The C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells* , 2004, Journal of Biological Chemistry.

[17]  D. Naisbitt,et al.  A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. , 2004, Toxicology.

[18]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[19]  Matej Oresic,et al.  Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. , 2004, Omics : a journal of integrative biology.

[20]  G. Olsson,et al.  The statin wars , 2003, The Lancet.

[21]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[22]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[23]  M. Wolzt,et al.  Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects , 2003, European Journal of Clinical Pharmacology.

[24]  C. Paweletz,et al.  Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells , 2003, Nature Immunology.

[25]  S. Kimball,et al.  The GCN2 eIF2α Kinase Is Required for Adaptation to Amino Acid Deprivation in Mice , 2002, Molecular and Cellular Biology.

[26]  A. Blom,et al.  Vitamin K-Dependent Protein S Localizing Complement Regulator C4b-Binding Protein to the Surface of Apoptotic Cells1 , 2002, The Journal of Immunology.

[27]  Geoffrey J McLachlan,et al.  Selection bias in gene extraction on the basis of microarray gene-expression data , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[29]  R. Ulrich,et al.  Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. , 2001, Chemico-biological interactions.

[30]  M. Cynader,et al.  Pyruvate Released by Astrocytes Protects Neurons from Copper-Catalyzed Cysteine Neurotoxicity , 2001, The Journal of Neuroscience.

[31]  Rocco Vivenzio.  Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine , 2001, Annals of Internal Medicine.

[32]  P. Taylor,et al.  A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo , 2000, The Journal of experimental medicine.

[33]  R. Mallet.  Pyruvate: metabolic protector of cardiac performance. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  D. Hume,et al.  Bacterial/CpG DNA down-modulates colony stimulating factor-1 receptor surface expression on murine bone marrow-derived macrophages with concomitant growth arrest and factor-independent survival. , 1999, Journal of immunology.

[35]  S. Valitutti,et al.  HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. , 1998, The Journal of clinical investigation.

[36]  J. Glowinski,et al.  Pyruvate Protects Neurons against Hydrogen Peroxide-Induced Toxicity , 1997, The Journal of Neuroscience.

[37]  L. Nencioni,et al.  Interleukin 2 down-modulates the macrophage colony-stimulating factor receptor in murine macrophages. , 1996, Cytokine.

[38]  R. Ulrich,et al.  Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon. , 1996, Toxicology.

[39]  H. Lange,et al.  The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients. , 1996, Clinical nephrology.

[40]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[41]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[42]  C. Nathan,et al.  Secretion of pyruvate. An antioxidant defense of mammalian cells , 1987, The Journal of experimental medicine.

[43]  P. Felig,et al.  Substrate, hormone, and temperature responses in males and females to a common breakfast. , 1980, Metabolism: clinical and experimental.

[44]  P. Srere.  The citrate enzymes: their structures, mechanisms, and biological functions. , 1972, Current topics in cellular regulation.

[45]  A. Wald.  Note on the Consistency of the Maximum Likelihood Estimate , 1949 .

[46]  W. James,et al.  Malnutrition , 1916, The Hospital.